Economic TimesLean R·
Lupin shares in focus after USFDA nod for drug to treat excessive daytime sleepiness
Lupin received USFDA approval for generic Pitolisant Tablets, strengthening its US portfolio and specialty generics presence. Shares remain technically weak despite strong long-term returns, with FIIs raising their stake while mutual fund holdings declined. The stock trades below most key moving averages, keeping near-term momentum subdued despite the positive regulatory development.
Read at Economic Times →
